On February 10, 2026 Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported the pricing of an underwritten offering of 7,868,383 shares of its common stock at a price of $13.98 per share. The gross proceeds from this offering are expected to be approximately $110.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about February 11, 2026, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering includes participation from new and existing investors, including BVF Partners L.P., Samsara BioCapital, Coastlands Capital, Eventide Asset Management, Perceptive Advisors, RA Capital Management, ADAR1 Capital Management, Affinity Asset Advisors and Acuta Capital Partners.

Leerink Partners, TD Cowen and LifeSci Capital are acting as joint bookrunning managers for the proposed offering.

Sutro intends to use the net proceeds of this offering, together with its existing cash, cash equivalents and marketable securities, primarily for general corporate purposes, which may include funding research, clinical and process development and manufacturing of its product candidates, increasing its working capital, acquisitions or investments in businesses, products or technologies that are complementary to the Company, capital expenditures and other general corporate purposes.

The securities are being offered by Sutro pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the prospectus supplement and the accompanying prospectus relating to this offering, may also be obtained, when available, from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected]; or LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at [email protected] Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at View Source

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Sutro, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Sutro Biopharma, FEB 10, 2026, View Source [SID1234662574])

On February 10, 2026 Sanofi reported that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 studies, and additional vaccine pipeline projects.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This acquisition augments Sanofi’s presence in adult immunization by bringing together Dynavax’s vaccines with Sanofi’s commercial reach, global scale, and development capabilities.

The tender offer for all outstanding shares of Dynavax common stock, par value $0.001 per share expired one minute after 11:59 P.M. EST, on February 9, 2026. The minimum condition and all the other conditions to the offer have been satisfied, and on February 10, 2026, Sanofi accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn.

Following its acceptance of the tendered shares, Sanofi completed its acquisition of Dynavax through the merger of a wholly owned subsidiary of Sanofi with and into Dynavax, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Dynavax continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi. In connection with the merger, all Dynavax shares not validly tendered in the tender offer have been converted into the right to receive the same $15.50 per share in cash, without interest, subject to any applicable withholding taxes, that would have been paid had such shares been validly tendered in the tender offer. As of February 10, 2026, Dynavax common stock will cease to be traded on the NASDAQ Global Select Stock Market.

(Press release, Sanofi, FEB 10, 2026, View Source [SID1234662573])

On February 10, 2026 Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, reported financial results for the fourth quarter and full year ended December 31, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We closed 2025 with a strong fourth quarter, and delivered double-digit growth in revenues and earnings per share for the full year," said Jim Davis, Chairman, CEO, and President. "Our robust performance demonstrates continued execution of our strategy to deliver category-defining clinical innovations that fulfill customers’ needs and to form strategic collaborations supporting growth. Our 2026 guidance reflects our continued confidence in our business strengths and market fundamentals."

Key 2025 Highlights:

Serving Clinicians and Health Systems

Began to deploy our largest Co-Lab Solutions implementation to date for Corewell Health, a leading health system in Michigan. Also finalized a laboratory-services joint venture with Corewell Health that includes plans to open a state-of-the-art laboratory in southeast Michigan in 2027.
Scaled lab testing to deliver services for more than 200,000 patients at Fresenius Medical Care’s dialysis centers in the United States while also adding leading water-purity testing capabilities to our menu.
Integrated eight acquisitions completed in 2024, providing the basis for growth in new geographies, including Canada.
Expanded and initiated new collaborations to serve in-network providers and members in new geographies.
Formed a first-of-its-kind collaboration with Epic to be our technology partner for Project Nova, our multi-year order-to-cash transformation to streamline systems and improve customer experiences, regardless of the electronic health record they use, for smarter, simpler testing.
Serving Consumers

Further advanced our position as the premier lab engine powering the wellness industry through questhealth.com, our consumer-initiated test platform, and through new collaborations with top consumer wellness and wearables companies.
Expanded our offerings on questhealth.com to more than 150 tests, including our new Elite Health Panel for assessing health based on over 85 biomarkers.
Delivering Clinical Innovations

Added category-defining innovations to our Advanced Diagnostics portfolio, including a new Quest AD-Detect blood test for aiding the diagnosis of Alzheimer’s disease, long-read gene sequencing to identify the cause of ataxia movement disorders, and HPV self-collection options for cervical cancer screening.
Secured FDA breakthrough device designation for the Haystack MRD test for monitoring patients treated for solid-tumor cancers.
Formed collaborations with The University of Texas MD Anderson Cancer Center and Rutgers Cancer Institute to research and develop innovations for detecting early signs of cancer.
Supported public health with Oropouche virus testing under a preparedness contract with the U.S. Centers for Disease Control and Prevention.
Driving Operational Excellence

Delivered 3% annual cost savings and productivity improvements through our Invigorate program.
Deployed AI and automation across lab, customer and administrative systems, including automated sample processing, logistics and cytology, improving quality, experiences and productivity.
Engaged Google Cloud to use generative AI to simplify and improve data management and analytics.

Three Months Ended December 31,

Twelve Months Ended December 31,

2025

2024

Change

2025

2024

Change

(dollars in millions, except per share data)

Reported:

Net revenues

$ 2,806

$ 2,621

7.1 %

$ 11,035

$ 9,872

11.8 %

Diagnostic information services revenues

$ 2,742

$ 2,556

7.3 %

$ 10,785

$ 9,614

12.2 %

Revenue per requisition

(0.1) %

0.1 %

Requisition volume

8.5 %

12.3 %

Organic requisition volume

7.9 %

3.4 %

Operating income (a)

$ 386

$ 361

7.0 %

$ 1,556

$ 1,346

15.6 %

Operating income as a percentage of net revenues
(a)

13.8 %

13.8 %

— %

14.1 %

13.6 %

0.5 %

Net income attributable to Quest Diagnostics (a)

$ 245

$ 222

10.7 %

$ 992

$ 871

13.9 %

Diluted EPS (a)

$ 2.18

$ 1.95

11.8 %

$ 8.75

$ 7.69

13.8 %

Cash provided by operations

$ 465

$ 464

0.5 %

$ 1,886

$ 1,334

41.4 %

Capital expenditures

$ 158

$ 123

27.4 %

$ 527

$ 425

23.8 %

Adjusted (a):

Operating income

$ 429

$ 409

4.7 %

$ 1,759

$ 1,541

14.1 %

Operating income as a percentage of net revenues

15.3 %

15.6 %

(0.3) %

15.9 %

15.6 %

0.3 %

Net income attributable to Quest Diagnostics

$ 273

$ 253

7.4 %

$ 1,118

$ 1,011

10.5 %

Diluted EPS

$ 2.42

$ 2.23

8.5 %

$ 9.85

$ 8.93

10.3 %

a)

For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.

Guidance for Full Year 2026

The company estimates its full year 2026 guidance in the table below. The company has included a presentation that includes additional guidance information on the Events and Presentations page of its investor relations website, which can be found at www.QuestDiagnostics.com/investor.

Low

High

Net revenues

$11.70 billion

$11.82 billion

Net revenues increase

6.0 %

7.1 %

Reported diluted EPS

$9.45

$9.65

Adjusted diluted EPS

$10.50

$10.70

Cash provided by operations

Approximately $1.75 billion

Capital expenditures

Approximately $550 million

Note on Non-GAAP Financial Measures

As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments, impairment charges and other items.

Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

Conference Call Information

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on February 10, 2026 until midnight Eastern Time on February 24, 2026, by phone at 866-388-5361 for domestic callers and 203-369-0416 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

(Press release, Quest Diagnostics, FEB 10, 2026, View Source [SID1234662572])

On February 10, 2026 Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer. Phio reported that the Safety Monitoring Committee (SMC) has concluded its planned safety review for all patients treated with the INTASYL compound PH-762 in Phio’s Phase 1b clinical trial. No dose-limiting toxicities or serious adverse events have been reported for any of the 22 enrolled patients who completed 4 intratumoral injections of PH-762 and have been followed through at least 4 weeks after the final injection. PH-762 has been evaluated in patients within five dose-escalating cohorts, increasing drug concentration 20-fold from the first to the fifth and final cohort.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These results support continued evaluation of this highest dose concentration of PH-762 in the next clinical trial" said Robert Bitterman, President and CEO of Phio Pharmaceuticals. "Reported pathological response coupled with a favorable safety-tolerability profile is clinically meaningful."

While final study data is pending formal analysis, an FDA submission intended to propose and seek guidance for next steps in clinical study design for PH-762 is targeted for the second quarter of 2026. A total of 22 patients with cutaneous carcinomas completed treatment in the Phase 1b trial and underwent excision of the treated lesional site. Revised reported data supports an overall response rate of 65% for squamous cell carcinomas (cSCC). Among the 20 patients with cSCC, 13 patients were classified as pathologic responders, including 9 patients with complete response (100% clearance), 2 patients with major/near clear response (greater than 90% clearance), and 2 patients with partial response (greater than 50% clearance). A single patient with metastatic Merkel cell carcinoma had a partial response. Seven cSCC patients and one melanoma patient had responses of less than 50%, however, none of the patients experienced a progression of the disease.

Concurrently, Chemistry, Manufacturing and Controls (CMC) development for drug substance material (API), is expected to have material available in March 2026 for the non-human primate study, a prerequisite for human pivotal trial commencement. Experimental work and documentation for process and methods development, as well as impurities testing are currently meeting expected timelines to commence manufacturing of cGMP material in the second half of 2026.

(Press release, Phio Pharmaceuticals, FEB 10, 2026, View Source [SID1234662571])

On February 10, 2026 Mabqi reported it’s participation in the World ADC Congress, taking place in London, UK, from February 23 to 26.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Widely regarded as the leading global event focused on antibody–drug conjugates (ADCs), the congress unites key stakeholders from across the entire ADC value chain — spanning early discovery, linker–payload innovations, and clinical translation.

During the event, Anne Chevrel will disclose new preclinical data on our lead pH-sensitive antibody–drug conjugate, showcasing our expertise in targeted delivery and enhanced therapeutic efficacy.

Our delegation will include:
• Anne Chevrel, Head of Discovery & Technology
• Sylvain Yon, CEO
• Cécile Durand, Business Development Director

We look forward to engaging with the global ADC community and discussing innovative strategies shaping the next generation of antibody–drug conjugates.

(Press release, Mabqi, FEB 10, 2026, View Source [SID1234662570])